PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.78%
Revenue growth of 4.78% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
0.79%
Gross profit growth of 0.79% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-4.47%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-1.53%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-4.66%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-4.66%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-4.66%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.86%
10Y CAGR of 82.86% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
82.86%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 2.00%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
63.59%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 8.99%. Joel Greenblatt might see a short-term competitive advantage at play.
100.00%
OCF/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 0.53% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
100.00%
3Y OCF/share growth of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
201.34%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 70.74% over a decade. Joel Greenblatt might see a standout compounder of earnings.
201.34%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 10.82%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
123.76%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 6.85%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
126.65%
Equity/share CAGR of 126.65% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
126.65%
5Y equity/share CAGR of 126.65% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
85.78%
3Y equity/share CAGR of 85.78% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-42.86%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-7.86%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-6.20%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
3.97%
BV/share growth of 3.97% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-22.28%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
1.48%
SG&A growth of 1.48% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.